Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 3
2015 1
2016 2
2017 2
2019 2
2020 7
2021 14
2022 17
2023 7
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics and Preclinical Safety Studies of Modified Endolysin-Based Gel for Topical Application.
Antonova NP, Vasina DV, Grigoriev IV, Usachev EV, Aleshkin AV, Vorobev AM, Laishevtsev AI, Kapustin AV, Savinov VA, Anurova MN, Zackharova AA, Remizov TA, Makarov VV, Yudin SM, Gushchin VA. Antonova NP, et al. Among authors: gushchin va. J Pharm Sci. 2024 Apr 29:S0022-3549(24)00156-4. doi: 10.1016/j.xphs.2024.04.028. Online ahead of print. J Pharm Sci. 2024. PMID: 38692487
Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response.
Mazunina EP, Gushchin VA, Kleymenov DA, Siniavin AE, Burtseva EI, Shmarov MM, Mukasheva EA, Bykonia EN, Kozlova SR, Evgrafova EA, Zolotar AN, Shidlovskaya EV, Kirillova ES, Krepkaia AS, Usachev EV, Kuznetsova NA, Ivanov IA, Dmitriev SE, Ivanov RA, Logunov DY, Gintsburg AL. Mazunina EP, et al. Among authors: gushchin va. Front Immunol. 2024 Apr 16;15:1381508. doi: 10.3389/fimmu.2024.1381508. eCollection 2024. Front Immunol. 2024. PMID: 38690272 Free PMC article.
Major Role of S-Glycoprotein in Providing Immunogenicity and Protective Immunity in mRNA Lipid Nanoparticle Vaccines Based on SARS-CoV-2 Structural Proteins.
Bykonia EN, Kleymenov DA, Gushchin VA, Siniavin AE, Mazunina EP, Kozlova SR, Zolotar AN, Usachev EV, Kuznetsova NA, Shidlovskaya EV, Pochtovyi AA, Kustova DD, Ivanov IA, Dmitriev SE, Ivanov RA, Logunov DY, Gintsburg AL. Bykonia EN, et al. Among authors: gushchin va. Vaccines (Basel). 2024 Apr 2;12(4):379. doi: 10.3390/vaccines12040379. Vaccines (Basel). 2024. PMID: 38675761 Free PMC article.
New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
Siniavin AE, Gushchin VA, Shastina NS, Darnotuk ES, Luyksaar SI, Russu LI, Inshakova AM, Shidlovskaya EV, Vasina DV, Kuznetsova NA, Savina DM, Zorkov ID, Dolzhikova IV, Sheremet AB, Logunov DY, Zigangirova NA, Gintsburg AL. Siniavin AE, et al. Among authors: gushchin va. Antiviral Res. 2024 May;225:105871. doi: 10.1016/j.antiviral.2024.105871. Epub 2024 Mar 28. Antiviral Res. 2024. PMID: 38555022 Free article.
Evaluation of molecular mechanisms of riboflavin anti-COVID-19 action reveals anti-inflammatory efficacy rather than antiviral activity.
Akasov RA, Chepikova OE, Pallaeva TN, Gorokhovets NV, Siniavin AE, Gushchin VA, Savvateeva LV, Vinokurov IA, Khochenkov DA, Zamyatnin AA Jr, Khaydukov EV. Akasov RA, et al. Among authors: gushchin va. Biochim Biophys Acta Gen Subj. 2024 May;1868(5):130582. doi: 10.1016/j.bbagen.2024.130582. Epub 2024 Feb 8. Biochim Biophys Acta Gen Subj. 2024. PMID: 38340879
Synthesis and Antiviral Activity of Novel β-D-N4-Hydroxycytidine Ester Prodrugs as Potential Compounds for the Treatment of SARS-CoV-2 and Other Human Coronaviruses.
Darnotuk ES, Siniavin AE, Shastina NS, Luyksaar SI, Inshakova AM, Bondareva NE, Zolotov SA, Lubenec NL, Sheremet AB, Logunov DY, Zigangirova NA, Gushchin VA, Gintsburg AL. Darnotuk ES, et al. Among authors: gushchin va. Pharmaceuticals (Basel). 2023 Dec 26;17(1):35. doi: 10.3390/ph17010035. Pharmaceuticals (Basel). 2023. PMID: 38256869 Free PMC article.
In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1.
Pochtovyi AA, Kustova DD, Siniavin AE, Dolzhikova IV, Shidlovskaya EV, Shpakova OG, Vasilchenko LA, Glavatskaya AA, Kuznetsova NA, Iliukhina AA, Shelkov AY, Grinkevich OM, Komarov AG, Logunov DY, Gushchin VA, Gintsburg AL. Pochtovyi AA, et al. Among authors: gushchin va. Vaccines (Basel). 2023 Sep 28;11(10):1533. doi: 10.3390/vaccines11101533. Vaccines (Basel). 2023. PMID: 37896937 Free PMC article.
61 results